Literature DB >> 30385253

Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs.

Adam L Halberstadt1, Muhammad Chatha2, Alexander Stratford3, Matthias Grill4, Simon D Brandt5.   

Abstract

In recent years, rigid analogs of phenylalkylamine hallucinogens have appeared as recreational drugs. Examples include 2-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)ethan-1-amine (2C-B-FLY) and 1-(8-bromobenzo[1,2-b;4,5-b']difuran-4-yl)-2-aminopropane (Bromo-DragonFLY, DOB-DFLY). Although some rigid compounds such as DOB-DFLY reportedly have higher potency than their non-rigid counterparts, it is not clear whether the same is true for 2C-B-FLY and other tetrahydrobenzodifurans. In the present study, the head twitch response (HTR), a 5-HT2A receptor-mediated behavior induced by serotonergic hallucinogens, was used to assess the effects of 2,5-dimethoxy-4-bromoamphetamine (DOB) and its α-desmethyl homologue 2,5-dimethoxy-4-bromophenethylamine (2C-B), as well as their benzodifuranyl and tetrahydrobenzodifuranyl analogs, in C57BL/6J mice. DOB (ED50 = 0.75 μmol/kg) and 2C-B (ED50 = 2.43 μmol/kg) induced the HTR. The benzodifurans DOB-DFLY (ED50 = 0.20 μmol/kg) and 2C-B-DFLY (ED50 = 1.07 μmol/kg) had significantly higher potency than DOB and 2C-B, respectively. The tetrahydrobenzodifurans DOB-FLY (ED50 = 0.67 μmol/kg) and 2C-B-FLY (ED50 = 1.79 μmol/kg), by contrast, were approximately equipotent with their non-rigid counterparts. Three novel tetrahydrobenzodifurans (2C-I-FLY, 2C-E-FLY and 2C-EF-FLY) were also active in the HTR assay but had relatively low potency. In summary, the in vivo potency of 2,5-dimethoxyphenylalkylamines is enhanced when the 2- and 5-methoxy groups are incorporated into aromatic furan rings, whereas potency is not altered if the methoxy groups are incorporated into dihydrofuran rings. The potency relationships for these compounds in mice closely parallel the human hallucinogenic data. The high potency of DOB-DFLY is probably linked to the presence of two structural features (a benzodifuran nucleus and an α-methyl group) known to enhance the potency of phenylalkylamine hallucinogens. Published by Elsevier Ltd.

Entities:  

Keywords:  2C-B-DragonFLY; 3C-B-FLY; 5-HT(2A) receptor; Head twitch; NPS; New psychoactive substance; Psychedelics

Mesh:

Substances:

Year:  2018        PMID: 30385253      PMCID: PMC6863604          DOI: 10.1016/j.neuropharm.2018.10.037

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

Review 1.  How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe.

Authors:  Raquel Santos-Toscano; Amira Guirguis; Colin Davidson
Journal:  Br J Clin Pharmacol       Date:  2020-02-23       Impact factor: 4.335

2.  Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Alexander Stratford; Simon P Elliott; Geraldine Dowling; Jason Wallach; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2019-06-18       Impact factor: 3.345

3.  Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice.

Authors:  Adam L Halberstadt; Muhammad Chatha; Stephen J Chapman; Simon D Brandt
Journal:  J Psychopharmacol       Date:  2019-02-21       Impact factor: 4.153

4.  Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; Jason Wallach; Simon D Brandt
Journal:  Neuropharmacology       Date:  2020-01-07       Impact factor: 5.273

5.  Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; John D McCorvy; Markus R Meyer; Lea Wagmann; Alexander Stratford; Simon D Brandt
Journal:  Neuropharmacology       Date:  2019-11-19       Impact factor: 5.273

Review 6.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

7.  Synthesis of Novel Benzodifuranyl; 1,3,5-Triazines; 1,3,5-Oxadiazepines; and Thiazolopyrimidines Derived from Visnaginone and Khellinone as Anti-Inflammatory and Analgesic Agents.

Authors:  Ameen Ali Abu-Hashem; Sami A Al-Hussain; Magdi E A Zaki
Journal:  Molecules       Date:  2020-01-05       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.